Novo Nordisk A/S (NVO)
| Previous Close | 128.64 |
| Open | 127.16 |
| Bid | 125.74 x 1200 |
| Ask | 125.79 x 1000 |
| Day's Range | 125.35 - 127.32 |
| 52 Week Range | 75.56 - 138.28 |
| Volume | |
| Avg. Volume | 5,036,312 |
| Market Cap | 561.414B |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | 47.31 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.37 (1.07%) |
| Ex-Dividend Date | Mar 22, 2024 |
| 1y Target Est | N/A |
- Investor's Business Daily
Weight Loss Leader Novo Nordisk Hits Buy Trigger In Stock Market Rebound
Novo Nordisk stock: The weight-loss drug leader hit a buy point in the recent stock market rebound and is one of the best stocks to watch.
- Zacks
4 Large Drug Stocks to Hold on to Amid Industry Challenges
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
- Reuters
About 3.6 mln Medicare beneficiaries could be eligible for Wegovy coverage, study shows
About 3.6 million overweight or obese patients with heart conditions insured under the U.S. Medicare program could be eligible for coverage of Novo Nordisk's weight-loss drug Wegovy, a study published by Kaiser Family Foundation (KFF) showed on Wednesday. Wegovy was approved by the U.S. health regulator last month for lowering the risk of stroke and heart attack in overweight or obese adults who do not have diabetes.
